Crescent Biopharma, a clinical-stage biotech company focusing on transformative oncology therapies, recently initiated global Phase 1/2 trials for its lead bispecific antibody CR-001 targeting PD-1 and VEGF, aiming to rival Keytruda. The firm is also advancing antibody drug conjugate candidates CR-002 and CR-003, with plans for monotherapy and combination trials in 2026. Financially, Crescent has yet to generate commercial revenue, sustaining significant losses and negative cash flows while maintaining a strong balance sheet with over $210 million in cash. Going forward, successful clinical data readouts and strategic partnerships will be critical to sustaining investor confidence and funding progression through costly development stages.